Hypogonadism Associations and Management

Associations Between Hypogonadism and Other Conditions

Testosterone replacement therapy in hypogonadal men frequently causes polycythemia as a known side effect, making this a direct association with hypogonadism treatment 1
Clinicians must monitor hematocrit levels in patients receiving testosterone therapy due to this established relationship 2
Testosterone replacement therapy, especially oral formulations, has been associated with potential hepatotoxicity 1
Transdermal testosterone is recommended for hypogonadal men specifically to avoid the hepatotoxic effects of oral testosterone formulations 3, 4
Guidelines specifically mention discussing "theoretical risks of hepatocellular carcinoma" when initiating testosterone therapy 5
Guidelines for hypogonadism do not identify hypocalcemia as a consequence of testosterone deficiency or treatment 2, 6, 7
While calcium metabolism is important in bone health (which can be affected by hypogonadism), hypocalcemia itself is not a direct result of hypogonadal states 8
Calcium supplementation (1g/day) along with vitamin D3 is recommended for patients with conditions that may accompany hypogonadism, suggesting that calcium levels are managed separately 3

When evaluating a patient with suspected hypogonadism, clinicians should monitor hematocrit for polycythemia, especially in patients on testosterone replacement 1
Clinicians should assess liver function due to potential hepatotoxicity concerns 1
The diagnostic workup for hypogonadism should include morning total testosterone levels using accurate and reliable assays 2
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) should be measured to distinguish between primary and secondary hypogonadism 6, 7
Sex hormone binding globulin (SHBG) assessment is recommended, especially in conditions where SHBG levels may be altered 7
Evaluation of clinical symptoms including sexual, physical, and psychological manifestations is necessary 7